Trevi Therapeutics (id:6743 TRVI)
2.91 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:58:11 PM)
Exchange closed, opens in 1 day 10 hours
About Trevi Therapeutics
Market Capitalization 219.84M
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
| Headquarters (address) |
195 Church Street New Haven 06510 CT United States |
| Phone | 203 304 2499 |
| Website | https://www.trevitherapeutics.com |
| Employees | 25 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | TRVI |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.970 - 4.00 |
| Market Capitalization | 219.84M |
| P/E trailing | -10.00 |
| P/E forward | -5.96 |
| Price/Book | 3.66 |
| Beta | 1.01 |
| EPS | -0.440 |
| EPS United States (ID:6, base:3403) | 24.22 |